Avidity Biosciences Inc. says will submit an application for accelerated approval to the FDA for del-zota before the end of ...
Avidity Biosciences (RNA) announced del-zota topline data from the Phase 1/2 EXPLORE44 trial in people living with Duchenne muscular dystrophy ...
Avidity Biosciences (RNA) announced positive del-zota topline data from the Phase 1/2 EXPLORE44 trial in people living with Duchenne muscular ...
GlobalData on MSN1d
Avidity’s del-zota elicits 25% increase in dystrophin in DMD patientsThe company plans to submit a biologics licence application to the US Food and Drug Administration later this year.
After some earlier data sparked questions from analysts, Avidity Biosciences has released more data for its RNA-based ...
SAN DIEGO - Avidity Biosciences, Inc. (NASDAQ:RNA), a biotechnology company with a market capitalization of $3.74 billion, has announced positive topline data from its Phase 1/2 EXPLORE44 trial ...
The EXPLORE44 study enrolled DMD patients with DMD mutations amenable to exon 44 skipping (DMD44), a group that accounts for around 6% of all DMD cases in the US. It showed a statistically ...
Del-zota produced statistically significant increases in exon skipping and dystrophin levels in EXPLORE44, a Phase 1/2 study in patients with DMD44 (oral presentation) Aravindhan Veerapandiyan, MD, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback